Rapid and Sensitive LC-MS-MS Method for the Simultaneous Estimation of Alfuzosin and Dutasteride in Human Plasma

A simple, rapid, specific and sensitive liquid chromatography-tandem mass spectrometric method has been developed and validated for the simultaneous estimation of alfuzosin and dutasteride in human plasma. Both alfuzosin and dutasteride were extracted from human plasma by solid-phase extraction using terazosin and finasteride as the internal standards for alfuzosin and dutasteride, respectively. Chromatographic separation of analytes and their respective internal standards was carried out using a Hypurity C18 (50 x 4.6 mm i.d., 5 mu m particle size) column followed by detection using an applied biosystems API 5000 mass spectrometer with a UPLC as the front end. The method involves a rapid solid phase extraction from plasma, simple isocratic chromatographic conditions and mass spectrometric detection in the positive ionization mode using multiple reactions monitoring that enables detection down to low nanogram levels with a total run time of 2.5 min only. The method was validated over a range of 0.25-20.0 ng mL(-1) for alfuzosin and 0.1-10.0 ng mL(-1) for dutasteride. The absolute recoveries for alfuzosin (65.57%), dutasteride (103.82%), terazosin (69.38%) and finasteride (102.25%) achieved from spiked plasma samples were consistent and reproducible. Acceptable precision and accuracy were obtained for concentrations over the standard curve ranges. Due to the short run time of 2.5 min it was possible to analyze a throughput of more than 180 human plasma samples per day. The validated method can be successfully used to analyze human plasma samples for application in pharmacokinetic, bioavailabilty or bioequivalence studies. As an example the application of this validated method to a bioequivalence study is also illustrated.